Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
Clinical Trial Results
Search
Dr. Nihar Desai and I discuss how practice is moving toward
We talk about the importance of MDs reviewing AI output and the timing of CT reassessment of risk Sponsored by […]
Dr. Brittany Weber and Dr. C. Michael Gibson discuss: Why Atherosclerosis is All That Really Matters: A Summary for Seamless Integration into Daily Clinical Practice
Sponsored by Cleerly, Women as One and International Atherosclerosis Society.
Dr. Roxana Mehran and Dr. C. Michael Gibson discuss: Unmet Needs in Coronary Atherosclerosis: A Discussion of Clinical Trial Designs for Evaluation of Asymptomatic and Symptomatic Patients
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Karim Al-Azizi and Dr. C. Michael Gibson discuss: Caveat Emptor: Advantages and Disadvantages of Current Generation Tools for Evaluation of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Fatima Rodriguez and Dr. C. Michael Gibson discuss: A Proposed Stepwise Approach to Evaluation, Treatment and Tracking of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Sandesh Dev and Dr. C. Michael Gibson discuss: Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.